Gastric adenocarcinoma burden, trends and survival in Cali, Colombia: A retrospective cohort study

被引:1
作者
Parra-Lara, Luis Gabriel [1 ,2 ]
Falla-Martinez, Juan Camilo [2 ]
Isaza-Pierotti, Daniel Francisco [2 ]
Mendoza-Urbano, Diana Marcela [2 ]
Tangua-Arias, Andres R. [2 ]
Bravo, Juan Carlos [3 ]
Bravo, Luis Eduardo [4 ]
Zambrano, Angela R. [5 ]
机构
[1] Univ Icesi, Fac Ciencias Salud, Cali, Colombia
[2] Fdn Valle Lili, Ctr Invest Clin, Cali, Colombia
[3] Fdn Valle Lili, Dept Patol, Cali, Colombia
[4] Univ Valle, Fac Salud, Dept Patol, Registro Poblac Canc Cali, Cali, Colombia
[5] Fdn Valle Lili, Dept Med Interna, Serv Hemato Oncol, Cali, Colombia
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
gastric cancer; lymphadenectomy; gastrectomy; gastric cancer survival; adjuvant chemotherapy; Helicobacter pylori; CANCER TREATMENT; MANAGEMENT; SURGERY; CLASSIFICATION; EPIDEMIOLOGY; SURVEILLANCE; CARCINOMA; D2;
D O I
10.3389/fonc.2023.1069369
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundGastric adenocarcinoma (GA) has changed in recent decades. Cancer estimates are often calculated from population-based cancer registries, which lack valuable information to guide decision-making (clinical outcomes). We describe the trends in clinical practice for GA using a hospital-based cancer registry over a timespan of 15 years. MethodsA retrospective cohort study was conducted. Data were gathered from adults diagnosed and treated for GA at Fundacion Valle del Lili (FVL), between 2000 and 2014, from the hospital's own cancer registry and crossed with Cali's Cancer Registry. Additional data were obtained directly from clinical records, pathology reports and the clinical laboratory. Patients younger than 18 years and those for whom limited information was available in the medical history were excluded. A survival analysis was conducted using Kaplan-Meier method. ResultsA total of 500 patients met eligibility criteria. Median age was 64 years (IQR: 54-74 years), 39.8% were female, 22.2% were at an early stage, 32.2% had a locally advanced disease, and 29% a metastatic disease, 69% had intestinal subtype, 48.6% had a positive H. pylori test, 85.2% had a distal lesion, 62% underwent gastrectomy, 60.6% lymphadenectomy, and 40.6% received chemotherapy. Survival at 5 years for all cases was 39.9% (CI 95% 35.3-44.5). Survival decreased over time in all groups and was lower in age-groups <39 and 60-79 with either locally advanced or metastatic disease. Prognostic factors that were significant in the Cox proportional-hazards model were late stages of the tumor (locally advanced: HR=2.52; metastatic: HR=4.17), diffuse subtype (HR=1.40), gastrectomy (subtotal: HR=0.42; total: 0.44) and palliative chemotherapy (HR=0.61). ConclusionsThe treatment of GA has changed in recent decades. GA survival was associated with clinical staging, diffuse subtype, gastrectomy and palliative chemotherapy. These findings must be interpreted in the context of a hospital-based study.
引用
收藏
页数:10
相关论文
共 38 条
[1]   Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J].
Al-Batran, Salah-Eddin ;
Homann, Nils ;
Pauligk, Claudia ;
Goetze, Thorsten O. ;
Meiler, Johannes ;
Kasper, Stefan ;
Kopp, Hans-Georg ;
Mayer, Frank ;
Haag, Georg Martin ;
Luley, Kim ;
Lindig, Udo ;
Schmiegel, Wolff ;
Pohl, Michael ;
Stoehlmacher, Jan ;
Folprecht, Gunnar ;
Probst, Stephan ;
Prasnikar, Nicole ;
Fischbach, Wolfgang ;
Mahlberg, Rolf ;
Trojan, Joerg ;
Koenigsmann, Michael ;
Martens, Uwe M. ;
Thuss-Patience, Peter ;
Egger, Matthias ;
Block, Andreas ;
Heinemann, Volker ;
Illerhaus, Gerald ;
Moehler, Markus ;
Schenk, Michael ;
Kullmann, Frank ;
Behringer, Dirk M. ;
Heike, Michael ;
Pink, Daniel ;
Teschendorf, Christian ;
Loehr, Carmen ;
Bernhard, Helga ;
Schuch, Gunter ;
Rethwisch, Volker ;
von Weikersthal, Ludwig Fischer ;
Hartmann, Joerg T. ;
Kneba, Michael ;
Daum, Severin ;
Schulmann, Karsten ;
Weniger, Joerg ;
Belle, Sebastian ;
Gaiser, Timo ;
Oduncu, Fuat S. ;
Guentner, Martina ;
Hozaeel, Wael ;
Reichart, Alexander .
LANCET, 2019, 393 (10184) :1948-1957
[2]   Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries [J].
Allemani, Claudia ;
Matsuda, Tomohiro ;
Di Carlo, Veronica ;
Harewood, Rhea ;
Matz, Melissa ;
Niksic, Maja ;
Bonaventure, Audrey ;
Valkov, Mikhail ;
Johnson, Christopher J. ;
Esteve, Jacques ;
Ogunbiyi, Olufemi J. ;
Azevedo e Silva, Gulnar ;
Chen, Wan-Qing ;
Eser, Sultan ;
Engholm, Gerda ;
Stiller, Charles A. ;
Monnereau, Alain ;
Woods, Ryan R. ;
Visser, Otto ;
Lim, Gek Hsiang ;
Aitken, Joanne ;
Weir, Hannah K. ;
Coleman, Michel P. .
LANCET, 2018, 391 (10125) :1023-1075
[3]   Registry of gastric cancer treatment evaluation (REGATE): I baseline disease characteristics [J].
Bang, Yung-Jue ;
Yalcin, Suayib ;
Roth, Arnaud ;
Hitier, Simon ;
Ter-Ovanesov, Mikhail ;
Wu, Chew-Wun ;
Zalcberg, John .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (01) :38-52
[4]   Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial [J].
Bang, Yung-Jue ;
Kim, Young-Woo ;
Yang, Han-Kwang ;
Chung, Hyun Cheol ;
Park, Young-Kyu ;
Lee, Kyung Hee ;
Lee, Keun-Wook ;
Kim, Yong Ho ;
Noh, Sang-Ik ;
Cho, Jae Yong ;
Mok, Young Jae ;
Kim, Yeul Hong ;
Ji, Jiafu ;
Yeh, Ta-Sen ;
Button, Peter ;
Sirzen, Florin ;
Noh, Sung Hoon .
LANCET, 2012, 379 (9813) :315-321
[5]   Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker [J].
Boccardi, Virginia ;
Marano, Luigi ;
Rossetti, Rosaria Rita Amalia ;
Rizzo, Maria Rosaria ;
di Martino, Natale ;
Paolisso, Giuseppe .
BMC CANCER, 2015, 15
[6]  
Bosman F. T., 2010, WHO classification of tumours of the digestive system
[7]   Clinicopathological Variation of Lauren Classification in Gastric Cancer [J].
Chen, Yun-Chi ;
Fang, Wen-Liang ;
Wang, Ruei-Fang ;
Liu, Chien-An ;
Yang, Muh-Hwa ;
Lo, Shu-Shun ;
Wu, Chew-Wen ;
Li, Anna Fen-Yau ;
Shyr, Yi-Ming ;
Huang, Kuo-Hung .
PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (01) :197-202
[8]   Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine [J].
Choi, Yoon Young ;
Noh, Sung Hoon ;
Cheong, Jae-Ho .
YONSEI MEDICAL JOURNAL, 2015, 56 (05) :1177-1185
[9]   Epidemiology of gastric cancer [J].
Crew, Katherine D. ;
Neugut, Alfred I. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (03) :354-362
[10]   Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].
Cunningham, David ;
Allum, William H. ;
Stenning, Sally P. ;
Thompson, Jeremy N. ;
Van de Velde, Cornelis J. H. ;
Nicolson, Marianne ;
Scarffe, J. Howard ;
Lofts, Fiona J. ;
Falk, Stephen J. ;
Iveson, Timothy J. ;
Smith, David B. ;
Langley, Ruth E. ;
Verma, Monica ;
Weeden, Simon ;
Chua, Yu Jo .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20